CD161 + CD127 + CD8 + T cell subsets can predict the efficacy of anti-PD-1 immunotherapy in non-small cell lung cancer with diabetes mellitus
Open Access
- 27 June 2024
- journal article
- research article
- Published by Taylor & Francis in OncoImmunology
- Vol. 13 (1) , 2371575
Abstract
The role of CD161+CD127+CD8+ T cells in non-small cell lung cancer (NSCLC) patients with diabetes remains unexplored. This study determined the prevalence, phenotype, and function of CD8+ T cell subsets in NSCLC with diabetes. We recruited NSCLC patients (n = 436) treated with anti-PD-1 immunotherapy as first-line treatment. The progression-free survival (PFS), overall survival (OS), T cells infiltration, and peripheral blood immunological characteristics were analyzed in NSCLC patients with or without diabetes. NSCLC patients with diabetes exhibited shorter PFS and OS (p = 0.0069 and p = 0.012, respectively) and significantly lower CD8+ T cells infiltration. Mass cytometry by time-of-flight (CyTOF) showed a higher percentage of CD161+CD127+CD8+ T cells among CD8+T cells in NSCLC with diabetes before anti-PD-1 treatment (p = 0.0071) than that in NSCLC without diabetes and this trend continued after anti-PD-1 treatment (p = 0.0393). Flow cytometry and multiple-immunofluorescence confirmed that NSCLC with diabetes had significantly higher CD161+CD127+CD8+ T cells to CD8+T cells ratios than NSCLC patients without diabetes. The RNA-sequencing analysis revealed immune-cytotoxic genes were reduced in the CD161+CD127+CD8+ T cell subset compared to CD161+CD127-CD8+ T cells in NSCLC with diabetes. CD161+CD127+CD8+ T cells exhibited more T cell-exhausted phenotypes in NSCLC with diabetes. NSCLC patients with diabetes with ≥ 6.3% CD161+CD127+CD8+ T cells to CD8+T cells ratios showed worse PFS. These findings indicate that diabetes is a risk factor for NSCLC patients who undergo anti-PD-1 immunotherapy.CD161+CD127+CD8+ T cells could be a key indicator of a poor prognosis in NSCLC with diabetes. Our findings would help in advancing anti-PD-1 therapy in NSCLC patients with diabetes.Keywords
Funding Information
- Natural Science Foundation of Zhejiang Province (LY23H160020)
- National Natural Science Foundation of China (81802278)
- Medicine Health Technology Plan of Zhejiang Province, China (2022KY150)
- General Project of Education Department of Zhejiang Province (Y202043420)
This publication has 65 references indexed in Scilit:
- CD161 Defines a Transcriptional and Functional Phenotype across Distinct Human T Cell LineagesCell Reports, 2014
- Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studiesBMJ, 2014
- A new link between diabetes and cancer: enhanced WNT/β-catenin signaling by high glucoseJournal of Molecular Endocrinology, 2013
- Diabetes mellitus as an independent risk factor for lung cancer: A meta-analysis of observational studiesEuropean Journal of Cancer, 2013
- Normalization of mass cytometry data with bead standardsCytometry Part A, 2013
- RETRACTED: High‐density lipoprotein of patients with type 2 diabetes mellitus elevates the capability of promoting migration and invasion of breast cancer cellsInternational Journal of Cancer, 2011
- Diabetes and CancerDiabetes Care, 2010
- Insulin—Carcinogen or Mitogen? Preclinical and Clinical Evidence from Prostate, Breast, Pancreatic, and Colorectal Cancer ResearchPostgraduate Medicine, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Activated T Lymphocytes in Type 2 Diabetes: Implications From in Vitro StudiesCurrent Drug Targets, 2003